AFT PHARMACEUTICALS LIMITED (AFP)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
AFP - AFT PHARMACEUTICALS LIMITED FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: March
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 1.53
Index:
FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: March
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 1.53
0
| LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
|---|---|---|---|
| $3.60 15 Oct |
OPEN $3.65 |
HIGH $3.65 | 36 LOW $3.60 |
-0.050| OTHER COMPANIES IN THE SAME SECTOR | |||
| 1AD . ACR . ACW . ADO . AGN . ARX . ATH . AVH . BIO . BOT . COV . CSL . CUV . DXB . GSS . HXL . IDT . ILA . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . OCC . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO . | |||
FNARENA'S MARKET CONSENSUS FORECASTS
- No Record -
Last ex-div: 18/06 - (franking ex-div 1.62c)
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
| Title | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| EPS Basic | xxx | xxx | xxx | xxx | xxx | 12.5 |
| DPS All | xxx | xxx | xxx | xxx | xxx | 2.6 |
| Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 226.3 M |
| Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 87.6 |
| Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | -10.4 M |
| Net Profit Margin | xxx | xxx | xxx | xxx | xxx | 5.78 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
| Title | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | 14.50 % |
| Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | 10.87 % |
| Return on Assets | xxx | xxx | xxx | xxx | xxx | 7.81 % |
| Return on Equity | xxx | xxx | xxx | xxx | xxx | 14.50 % |
| Return on Total Capital | xxx | xxx | xxx | xxx | xxx | 17.57 % |
| Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | -12.2 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
| Title | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Short-Term Debt | xxx | xxx | xxx | xxx | xxx | 10 M |
| Long Term Debt | xxx | xxx | xxx | xxx | xxx | 35 M |
| Total Debt | xxx | xxx | xxx | xxx | xxx | 45 M |
| Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | - |
| Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 9 M |
| Price To Book Value | xxx | xxx | xxx | xxx | xxx | 3.20 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
| Title | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capex | xxx | xxx | xxx | xxx | xxx | 8.7 M |
| Capex % of Sales | xxx | xxx | xxx | xxx | xxx | 3.83 % |
| Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | 128 M |
| Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 76 M |
| Research & Development | xxx | xxx | xxx | xxx | xxx | 10 M |
| Investments - Total | xxx | xxx | xxx | xxx | xxx | 0 M |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
EXTRA COVERAGE
Display All Commentary
No. Of Recommendations
Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.
AFP STOCK CHART
FNArena News on AFP
| 1 | Australian Broker Call *Extra* Edition – Oct 08, 2026Oct 08 2026 - Daily Market Reports |
| 2 | Australian Broker Call *Extra* Edition – May 25, 2026May 25 2026 - Daily Market Reports |
| 3 | Australian Broker Call *Extra* Edition – Apr 01, 2026Apr 01 2026 - Daily Market Reports |
| 4 | Australian Broker Call *Extra* Edition – Aug 06, 2025Aug 06 2025 - Daily Market Reports |
| 5 | Next Week At A Glance – 24-28 Jun 2024Jun 21 2024 - Weekly Reports |
Latest Pharmaceuticals & Biotech/Lifesciences News
| 1 | Telix Aims For A Strategic Isotope Supply ChainSep 24 2026 - Australia |
| 2 | CSL’s FY26 Suggests The Downtrend Is DoneAug 19 2026 - Australia |
| 3 | Strong Result, Can Telix Continue To Deliver?Jul 22 2026 - Australia |
| 4 | CSL Challenges Pile On, Where’s The Upside?May 13 2026 - Australia |
| 5 | The Biotech ‘Industrialisation’Apr 20 2026 - Small Caps |
| 6 | Telix’ Double-Product Strategy On A RollApr 10 2026 - Australia |
| 7 | Focus On Telix’ Guidance Post Annus HorribilisJan 22 2026 - Australia |
| 8 | Anti-Vaxxers & China Cloud CSL’s FutureOct 31 2025 - Australia |
| 9 | Rudi Interviewed: Diary Of A Successful InvestorOct 20 2025 - Rudi's View |
| 10 | Is CSL Starting Its Price Recovery?Sep 30 2025 - Technicals |